Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical device
|
| gptkbp:advantage |
Longer Shelf Life
No Need for Blood Typing Reduced Risk of Disease Transmission |
| gptkbp:alsoKnownAs |
gptkb:Blood_Substitute
|
| gptkbp:benefit |
Immediate Availability
No Cross-Matching Required Useful in Remote Locations |
| gptkbp:developedBy |
gptkb:Emergency_Medicine
Surgery Trauma Care Military Medicine Patients with Rare Blood Types |
| gptkbp:excludes |
Human Blood Cells
Plasma Proteins |
| https://www.w3.org/2000/01/rdf-schema#label |
Artificial Blood
|
| gptkbp:limitation |
Limited Oxygen Carrying Capacity
Potential Side Effects Short Circulation Time |
| gptkbp:notableCase |
gptkb:Hemopure_Clinical_Studies
gptkb:Oxygent_Clinical_Trials gptkb:PolyHeme_Phase_III_Clinical_Trial |
| gptkbp:product |
gptkb:Sanguinate
gptkb:Hemopure gptkb:PolyHeme Oxygent |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA gptkb:Health_Canada Not Widely Approved for Clinical Use |
| gptkbp:relatedTo |
gptkb:Perfluorocarbons
gptkb:Red_Blood_Cells Transfusion Medicine Hemoglobin Blood Donation |
| gptkbp:researchedSince |
1980s
|
| gptkbp:riskFactor |
gptkb:Methemoglobinemia
Hypertension Allergic Reactions Renal Toxicity |
| gptkbp:studiedBy |
Academic Institutions
Biotechnology Companies Military Research Organizations |
| gptkbp:type |
Hemoglobin-Based Oxygen Carriers
Perfluorocarbon-Based Oxygen Carriers Stem Cell-Derived Red Blood Cells |
| gptkbp:usedFor |
gptkb:Blood_Transfusion
Oxygen Delivery Volume Expansion |
| gptkbp:bfsParent |
gptkb:Blood_Substitute
|
| gptkbp:bfsLayer |
7
|